This Article Full Text Full Text (PDF) All Versions of this Article: 51/1/45    most recent HYPERTENSIONAHA.107.101329v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Grouzmann, E. Articles by Buclin, T. Search for Related Content PubMed PubMed Citation Articles by Grouzmann, E. Articles by Buclin, T. Related Collections Primary prevention ACE/Angiotension receptors Other hypertension Type 2 diabetes Related Article

(Hypertension. 2008;51:45.)
© 2008 American Heart Association, Inc.

Editorial Commentaries

Is Dipeptidylpeptidase IV the Missing Link in Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema?

Eric Grouzmann; Thierry Buclin

From the Division of Clinical Pharmacology and Toxicology, Lausanne University Medical School, Lausanne, Switzerland.

Correspondence to Eric Grouzmann, Division of Clinical Pharmacology and Toxicology, Lausanne University Medical School, 1011, Lausanne, Switzerland. E-mail eric.grouzmann@chuv.ch

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Approximately 40 million people worldwide are currently treated with angiotensin-converting enzyme (ACE) inhibitors (ACEIs) for hypertension, congestive heart failure, coronary diseases, and diabetic nephropathy. The primary mechanism of action of ACEIs is blocking of the renin angiotensin system by inhibiting the conversion of angiotensin I to the vasoconstrictor angiotensin II. Few serious adverse events specific to ACE inhibition were initially reported, because they are actually rare. However, 0.68 of every 100 patients seem to experience angioedema with ACEI, sometimes months and even years after the start of medication.¹ The pathophysiology of ACEI-induced angioedema is presently thought to result from the role of ACE in the degradation of other peptides including bradykinin (BK) and substance P (SP).² These proinflammatory peptides are released by sensory nerves during inflammation.³ Both peptides elicit plasma exudation from postcapillary venules, leading to interstitial edema and affecting tissue function.³

	What Do We Know About BK and SP Degradation?

 
The metabolism of BK and SP by proteases is redundant, with several enzymes available to terminate their biological action. Both ACE and neutral endopeptidase (NEP) play major roles in inactivating BK and SP.² BK is also processed by aminopeptidase P, but a contribution of this peptidase in angioedema during ACEI is unlikely, despite a downregulation of its activity reported in some cases.⁴ BK is also a substrate of kininase I, capable of cleaving the last residue off its C-terminal end to generate des-Arg⁹-BK, a fragment without affinity for the B2 receptor but an agonist on the inducible B1 receptor expressed during inflammation.⁴ On the other hand, SP . . . [Full Text of this Article]

Related Article:

Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema

James Brian Byrd, Karine Touzin, Saba Sile, James V. Gainer, Chang Yu, John Nadeau, Albert Adam, and Nancy J. Brown
Hypertension 2008 51: 141-147. [Abstract] [Full Text] [PDF]